LMU-founded antibody reagent supplier ChromoTek has been picked up after raising funding from Bayern Kapital and HTGF in 2010.
ChromoTek, a Germany-based proteomic reagent materials supplier spun out of Ludwig Maximilian University of Munich, has been acquired by antibody tools supplier Proteintech for an undisclosed sum.
Founded in 2008, ChromoTek supplies alpaca single-domain antibodies tailored to conducting proteomic analysis in various pharmaceutical and biological research settings.
The offering will be combined with Proteintech’s portfolio in order to strengthen its appeal in areas such as single-cell and multiplex biological analysis.
Chromotek secured €400,000 ($513,000) in 2010 from public-private partnership High-Tech Gründerfonds and Bavarian state-owned investment firm Bayern Kapital, according to trade paper Science Business.
Marion Jung, chief executive of ChromoTek, said: “Our fit-for-purpose nanobody-based tools perfectly complement the comprehensive antibody coverage of the proteome that Proteintech offers.
“It is exciting to be working together with a company that shares our values in reproducibility and quality for the benefit of research and beyond.”
